Tag: Biocon

Remain focused on companies with exposure to Indian markets, says India Infoline

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

Listen to the Article (6 Minutes)

India Infoline, a financial service firm issued a report on pharmaceutical companies, specifically analyzing US business margins.

The report suggested that there has been a 1,200 bps kind of a margin erosion for Indian companies which are serving the US generic markets as a whole.  Out of that, half of the margin erosion has come because of the price pressure and the other half has come because of the increased R&D activities.

“We essentially remain focused on companies which have a higher share of EBITDA coming out of India and other markets as compared to US where we still see challenges going forward in terms of pricing pressure continuing”, said Abhishek Sharma, Vice President and Pharma Analyst at IIFL.

“On that parameter, we would essentially like companies like Torrent and Alkem Labs, which still continue to derive a lion share of their EBITDA from this market”, he further added.

Sharma also stated that Biocon has efficiently played out in the last one to one and a half years.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow